STK11 and neoplasm: STK11 loss occurs in approximately 15% of lung adenocarcinomas and is associated with a lack of PD-L1 expression, reduced tumor-infiltrating cytotoxic CD8+ T lymphocytes, and resistance to ICI in patients with KRAS mutant NSCLC.